Scarica l'app Stockscreener
7.31
5.19%
-0.40
Dopo l'orario di chiusura:
7.33
0.02
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.71
Aprire:
$7.79
Volume 24 ore:
2.04M
Relative Volume:
1.64
Capitalizzazione di mercato:
$569.52M
Reddito:
$14.79M
Utile/perdita netta:
$-102.44M
Rapporto P/E:
-2.4046
EPS:
-3.04
Flusso di cassa netto:
$-91.73M
1 W Prestazione:
+8.30%
1M Prestazione:
+18.09%
6M Prestazione:
+35.62%
1 anno Prestazione:
+42.08%
Intervallo 1D:
$7.16
$7.84
Intervallo di 1 settimana:
$6.60
$8.72
Portata 52W:
$2.41
$8.72
Solid Biosciences Inc Stock (SLDB) Company Profile
Nome
Solid Biosciences Inc
Settore
Industria
Telefono
617-337-4680
Indirizzo
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
7.31 | 569.52M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Iniziato | Needham | Buy |
| 2025-06-26 | Iniziato | Citigroup | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-13 | Iniziato | Wedbush | Outperform |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-15 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | William Blair | Outperform |
| 2024-03-15 | Iniziato | Citigroup | Buy |
| 2024-03-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-05-27 | Iniziato | Jefferies | Buy |
| 2021-03-16 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Iniziato | Evercore ISI | Outperform |
| 2019-08-29 | Downgrade | Citigroup | Neutral → Sell |
| 2019-08-19 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Downgrade | Goldman | Neutral → Sell |
| 2019-02-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-02-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Iniziato | Citigroup | Sell |
| 2018-09-06 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union
Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Nigeria
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com Canada
Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union
Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - Yahoo Finance
Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Bain Capital Life Sciences (SLDB) caps Solid Biosciences stake at 9.99% after PIPE - Stock Titan
RA Capital details 9.9% Solid Biosciences (SLDB) ownership position - Stock Titan
Barclays Maintains Solid Biosciences (SLDB) Overweight Recommendation - MSN
Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle
Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat
Solid Biosciences secures $240M private placement funding By Investing.com - Investing.com Canada
Solid Biosciences Announces $240 Million Private Placement Financing - TipRanks
Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding - marketscreener.com
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Bitget
Solid Biosciences (SLDB) Announces $240M Private Placement - GuruFocus
Solid Biosciences Announces Oversubscribed $240 Million Private Placement - Bitget
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences secures $240M private placement funding - Investing.com India
Solid Biosciences Commences $240 Million Private Placement of Common Shares, Pre-Funded Warrants - marketscreener.com
Solid Biosciences stock jumps on $240M private placement - Investing.com
Solid Biosciences stock jumps on $240M private placement By Investing.com - Investing.com Nigeria
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences (SLDB) Stock Price, News & Analysis - MarketBeat
Biotech Sector Sustains After-Hours Trading Gains - Intellectia AI
Solid Biosciences (SLDB) Projected to Post Earnings on Thursday - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome - Traders Union
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Solid Biosciences CTO Herzich sells $21k in shares By Investing.com - Investing.com South Africa
Solid Biosciences Inc Azioni (SLDB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):